CO5021135A1 - Compuestos quimicos - Google Patents
Compuestos quimicosInfo
- Publication number
- CO5021135A1 CO5021135A1 CO98065179A CO98065179A CO5021135A1 CO 5021135 A1 CO5021135 A1 CO 5021135A1 CO 98065179 A CO98065179 A CO 98065179A CO 98065179 A CO98065179 A CO 98065179A CO 5021135 A1 CO5021135 A1 CO 5021135A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- alq
- group
- optionally substituted
- ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Un compuesto de la fórmula (I) el cual es un agonista en elreceptor de la adenosina A1en donde R2 representa alquilo con 1 a 3 átomos de carbono, halógeno o hidrógeno;R3 representa un grupo alquilo recto o ramificado, fluorado, de 1-6 átomos de carbono;R1 representa un grupo seleccionado de(1) -(alq)n -(C3-7 ) cicloalquilo, que incluyen el cicloalquilo con puentes, el grupo cicloalquilo que está substituido opcionalmente por uno o más de los substituyentes seleccionados de OH, halógeno, -(C1-3 ) alcoxi, en donde (alq) representa alquileno con C1-3 y n representa 0 ó 1.(2) un grupo heterocíclico alifático de anillos de 4 a 6 elementos que contienen al menos un heteroátomo seleccionado de O, N, o S, substituido opcionalmente por uno o más substituyentes seleccionados del grupo que consiste de -(C1-3 )alquilo, -CO2 - (C1-4 )alquilo, -CO(C1-3 alquilo), -S(=O)n - (C1-3 alquilo), -CONRa Rb (en donde Ra y Rb representan independientemente H o C1-3 alquilo) o =O; en donde existe un átomo de azufre en el anillo heterocíclico, y el azufre está substituido opcionalmente por (=O)n , en donde n es 1 o 2.(3) alquilo con C1-12 recto o ramificado que incluye opcionalmente uno o más O,S(=O)n (en donde n es 0, 1 ó 2) o grupos N substituidos dentro de la cadena de alquilo, el alquilo substituido opcionalmente por uno o más de los siguientes grupos, fenilo, halógeno, hidroxi o NRa Rb en donde Ra y Rb ambos representan C1-3 alquilo o hidrógeno.(4) un anillo aromático bicíclico fusionado - 2 -en donde B representa un grupo aromático heterocíclico de 5 o 6 elementos que contiene 1 o más átomos de O, N o S, en donde el anillo bicíclico está unido al átomo de nitrógeno de la fórmula (I) por medio de un átomo del anillo, del anillo A, y el anillo B está substituido opcionalmente por -CO2 -(C1-3 alquilo).(5) un grupo fenilo substituido opcionalmente por uno o más substituyentes seleccionados de:-halógeno -SO3 H, (alq)n OH, -(alq)n ciano, -(O)n -(C1-6 )alquilo (substituido opcionalmente por uno o más halógenos), -(alq)n - nitro, -(O)m -(alq)n -CO2 Rc , -(alq)n -CONRc Rd -(alq)n -CORc , -(alq)n -SORe , -(alq)n SO2 Re , -(alq)n SO2 NRc Rd , -(alq)n ORc , -(alq)n -(CO)m -NHSO2 Re , -(alq)n -NHCORc , -(alq)n -NRc Rd en donde m y n son 0 ó 1 y alq representa un grupo C1-6 alquileno o un grupo C2-6 alquenilo.(6) un grupo fenilo substituido por un grupo aromático haterocíclico de 5 o 6 elementos, el grupo aromático heterocíclico está substituido opcionalmente por C1-3 alquilo o NRc Rd Rc y Rd pueden representar cada uno independientemente hidrógeno, o C1-3 alquilo y cuando forma parte de un grupo NRc Rd , Rc y Rd junto con el átomo de nitrógeno pueden formar un anillo heterocíclico de 5 o 6 elementos que contiene opcionalmente otros heteroátomos, tal anillo heterocíclico puede estar substituido opcionalmente de manera adicional por uno o más grupos C1-3 alquilo.Re representa C1-3 alquiloy la sales y los solvatos de los mimos, en particular, las sales y solvatos de los mismos aceptables fisiologicamente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9723589.9A GB9723589D0 (en) | 1997-11-08 | 1997-11-08 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5021135A1 true CO5021135A1 (es) | 2001-03-27 |
Family
ID=10821760
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO98065179A CO5021135A1 (es) | 1997-11-08 | 1998-11-05 | Compuestos quimicos |
Country Status (29)
Country | Link |
---|---|
US (1) | US6455510B1 (es) |
EP (2) | EP1030857B1 (es) |
JP (1) | JP2001522857A (es) |
KR (1) | KR20010031875A (es) |
CN (1) | CN1285843A (es) |
AP (1) | AP2000001801A0 (es) |
AR (1) | AR011229A1 (es) |
AT (1) | ATE273990T1 (es) |
AU (1) | AU2048399A (es) |
BR (1) | BR9813976A (es) |
CA (1) | CA2309200A1 (es) |
CO (1) | CO5021135A1 (es) |
DE (1) | DE69825780T2 (es) |
EA (1) | EA200000392A1 (es) |
EE (1) | EE200000285A (es) |
ES (1) | ES2222621T3 (es) |
GB (1) | GB9723589D0 (es) |
HR (1) | HRP20000275A2 (es) |
HU (1) | HUP0004082A2 (es) |
IL (1) | IL135964A0 (es) |
IS (1) | IS5477A (es) |
MA (1) | MA26565A1 (es) |
NO (1) | NO20002361L (es) |
PE (1) | PE20000013A1 (es) |
PL (1) | PL340921A1 (es) |
SK (1) | SK6722000A3 (es) |
TR (1) | TR200002131T2 (es) |
WO (1) | WO1999024449A2 (es) |
ZA (1) | ZA9810125B (es) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9723589D0 (en) * | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
US7214665B2 (en) | 2001-10-01 | 2007-05-08 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof |
US20040162422A1 (en) * | 2001-03-20 | 2004-08-19 | Adrian Hall | Chemical compounds |
GB0106867D0 (en) | 2001-03-20 | 2001-05-09 | Glaxo Group Ltd | Process |
US6946449B2 (en) | 2001-07-13 | 2005-09-20 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
US7713946B2 (en) | 2002-07-11 | 2010-05-11 | Cv Therapeutics, Inc. | Partial and full agonists A1 adenosine receptors |
US7157440B2 (en) | 2001-07-13 | 2007-01-02 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
EP1375508A1 (en) * | 2002-06-27 | 2004-01-02 | Aventis Pharma Deutschland GmbH | N6-substituted adenosine analogues and their use as pharmaceutical agents |
US7265111B2 (en) * | 2002-06-27 | 2007-09-04 | Sanofi-Aventis Deutschland Gmbh | Adenosine analogues and their use as pharmaceutical agents |
FR2842810B1 (fr) * | 2002-07-25 | 2006-01-27 | Inst Nat Sciences Appliq | Nouveaux composes gem difluores, leur procedes de preparation et leurs applications. |
AU2003263846B2 (en) * | 2002-08-15 | 2009-12-17 | Gilead Palo Alto, Inc. | Partial and full agonists of A1 adenosine receptors |
EP1590359A2 (en) | 2003-02-03 | 2005-11-02 | CV Therapeutics Inc. | PARTIAL AND FULL AGONISTS OF A sb 1 /sb ADENOSINE RECEPTORS |
AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
CA2601996A1 (en) * | 2004-09-09 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Purine derivatives as a3 and a1 adenosine receptor agonists |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
KR20080049113A (ko) | 2005-10-21 | 2008-06-03 | 노파르티스 아게 | Il-13에 대항한 인간 항체 및 치료적 용도 |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
US8178509B2 (en) * | 2006-02-10 | 2012-05-15 | University Of Virginia Patent Foundation | Method to treat sickle cell disease |
US8188063B2 (en) * | 2006-06-19 | 2012-05-29 | University Of Virginia Patent Foundation | Use of adenosine A2A modulators to treat spinal cord injury |
ATE502943T1 (de) | 2006-09-29 | 2011-04-15 | Novartis Ag | Pyrazolopyrimidine als pi3k-lipidkinasehemmer |
EP2089393A1 (en) | 2006-10-30 | 2009-08-19 | Novartis AG | Heterocyclic compounds as antiinflammatory agents |
US8058259B2 (en) * | 2007-12-20 | 2011-11-15 | University Of Virginia Patent Foundation | Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists |
BRPI0907248A2 (pt) * | 2008-01-09 | 2019-02-26 | Pgxhealth, Llc | tratamento intratecal de dor neuropática com agonistas a2ar |
JP5584138B2 (ja) | 2008-01-11 | 2014-09-03 | ノバルティス アーゲー | キナーゼ阻害剤としてのピリミジン類 |
JP2012516345A (ja) | 2009-01-29 | 2012-07-19 | ノバルティス アーゲー | 星細胞腫治療用置換ベンゾイミダゾール |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
AU2010283806A1 (en) | 2009-08-12 | 2012-03-01 | Novartis Ag | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
ES2709108T3 (es) | 2009-08-17 | 2019-04-15 | Intellikine Llc | Compuestos heterocíclicos y usos de los mismos |
AU2010284972A1 (en) | 2009-08-20 | 2012-03-08 | Novartis Ag | Heterocyclic oxime compounds |
UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
EP2673277A1 (en) | 2011-02-10 | 2013-12-18 | Novartis AG | [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase |
US9127000B2 (en) | 2011-02-23 | 2015-09-08 | Intellikine, LLC. | Heterocyclic compounds and uses thereof |
WO2012116217A1 (en) | 2011-02-25 | 2012-08-30 | Irm Llc | Compounds and compositions as trk inhibitors |
DE102011005232A1 (de) | 2011-03-08 | 2012-09-13 | AristoCon GmbH & Co. KG | Adenosin und seine Derivate zur Verwendung in der Schmerztherapie |
BR112014006223A8 (pt) | 2011-09-15 | 2018-01-09 | Novartis Ag | 3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas 6-substituídas, seus usos, composições farmacêuticas, e combinação |
JP6130391B2 (ja) | 2011-11-23 | 2017-05-17 | インテリカイン, エルエルシー | Mtor阻害剤を使用する強化された治療レジメン |
CN104245701A (zh) | 2012-04-03 | 2014-12-24 | 诺华有限公司 | 有酪氨酸激酶抑制剂的组合产品和其应用 |
EP2968340A4 (en) | 2013-03-15 | 2016-08-10 | Intellikine Llc | COMBINING KINASE INHIBITORS AND USES THEREOF |
WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
MX2017001461A (es) | 2014-07-31 | 2017-05-11 | Novartis Ag | Terapia de combinacion. |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3575959A (en) * | 1969-05-13 | 1971-04-20 | Merck & Co Inc | 5'-substituted ribofuranosyl nucleosides |
US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
WO1997033591A1 (en) * | 1996-03-13 | 1997-09-18 | Novo Nordisk A/S | A method of treating disorders related to cytokines in mammals |
GB9610031D0 (en) * | 1996-05-14 | 1996-07-17 | Glaxo Group Ltd | Chemical compounds |
GB9723589D0 (en) * | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
-
1997
- 1997-11-08 GB GBGB9723589.9A patent/GB9723589D0/en not_active Ceased
-
1998
- 1998-11-05 CO CO98065179A patent/CO5021135A1/es unknown
- 1998-11-05 PE PE1998001065A patent/PE20000013A1/es not_active Application Discontinuation
- 1998-11-05 MA MA25336A patent/MA26565A1/fr unknown
- 1998-11-05 AR ARP980105590A patent/AR011229A1/es unknown
- 1998-11-05 ZA ZA9810125A patent/ZA9810125B/xx unknown
- 1998-11-06 DE DE1998625780 patent/DE69825780T2/de not_active Expired - Fee Related
- 1998-11-06 SK SK672-2000A patent/SK6722000A3/sk unknown
- 1998-11-06 KR KR1020007004959A patent/KR20010031875A/ko not_active Application Discontinuation
- 1998-11-06 EA EA200000392A patent/EA200000392A1/ru unknown
- 1998-11-06 EP EP98965151A patent/EP1030857B1/en not_active Expired - Lifetime
- 1998-11-06 CN CN98812979A patent/CN1285843A/zh active Pending
- 1998-11-06 AT AT98965151T patent/ATE273990T1/de not_active IP Right Cessation
- 1998-11-06 PL PL98340921A patent/PL340921A1/xx unknown
- 1998-11-06 JP JP2000520457A patent/JP2001522857A/ja active Pending
- 1998-11-06 BR BR9813976-2A patent/BR9813976A/pt not_active Application Discontinuation
- 1998-11-06 US US09/530,573 patent/US6455510B1/en not_active Expired - Fee Related
- 1998-11-06 AU AU20483/99A patent/AU2048399A/en not_active Abandoned
- 1998-11-06 CA CA002309200A patent/CA2309200A1/en not_active Abandoned
- 1998-11-06 EE EEP200000285A patent/EE200000285A/xx unknown
- 1998-11-06 WO PCT/EP1998/007021 patent/WO1999024449A2/en active IP Right Grant
- 1998-11-06 IL IL13596498A patent/IL135964A0/xx unknown
- 1998-11-06 AP APAP/P/2000/001801A patent/AP2000001801A0/en unknown
- 1998-11-06 HU HU0004082A patent/HUP0004082A2/hu unknown
- 1998-11-06 TR TR2000/02131T patent/TR200002131T2/xx unknown
- 1998-11-06 EP EP04076482A patent/EP1457495A1/en not_active Withdrawn
- 1998-11-06 ES ES98965151T patent/ES2222621T3/es not_active Expired - Lifetime
-
2000
- 2000-05-03 IS IS5477A patent/IS5477A/is unknown
- 2000-05-05 NO NO20002361A patent/NO20002361L/no not_active Application Discontinuation
- 2000-05-08 HR HR20000275A patent/HRP20000275A2/hr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO1999024449A3 (en) | 1999-08-19 |
EP1457495A1 (en) | 2004-09-15 |
BR9813976A (pt) | 2000-09-26 |
AU2048399A (en) | 1999-05-31 |
EA200000392A1 (ru) | 2000-12-25 |
DE69825780T2 (de) | 2005-01-13 |
CN1285843A (zh) | 2001-02-28 |
ATE273990T1 (de) | 2004-09-15 |
AP2000001801A0 (en) | 2000-06-30 |
HRP20000275A2 (en) | 2000-12-31 |
AR011229A1 (es) | 2000-08-02 |
EP1030857A2 (en) | 2000-08-30 |
IL135964A0 (en) | 2001-05-20 |
HUP0004082A2 (hu) | 2001-04-28 |
US6455510B1 (en) | 2002-09-24 |
PL340921A1 (en) | 2001-03-12 |
EE200000285A (et) | 2001-08-15 |
WO1999024449A2 (en) | 1999-05-20 |
ZA9810125B (en) | 2000-05-05 |
KR20010031875A (ko) | 2001-04-16 |
SK6722000A3 (en) | 2001-01-18 |
EP1030857B1 (en) | 2004-08-18 |
NO20002361D0 (no) | 2000-05-05 |
ES2222621T3 (es) | 2005-02-01 |
TR200002131T2 (tr) | 2001-01-22 |
GB9723589D0 (en) | 1998-01-07 |
DE69825780D1 (de) | 2004-09-23 |
MA26565A1 (fr) | 2004-12-20 |
PE20000013A1 (es) | 2000-01-21 |
IS5477A (is) | 2000-05-03 |
JP2001522857A (ja) | 2001-11-20 |
CA2309200A1 (en) | 1999-05-20 |
NO20002361L (no) | 2000-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5021135A1 (es) | Compuestos quimicos | |
CO5070570A1 (es) | DERIVADOS DE TIROSINA COMO ACTIVADORES DE hPPAR Y hPPARalfa Y UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE | |
CO5540344A2 (es) | Medicamentos | |
AR018917A1 (es) | Compuestos derivados de adenosina que son agonistas en el receptor adenosina a1, proceso para su preparacion, composiciones farmaceuticas que los contienen. | |
AR033735A1 (es) | Compuestos de alfa-aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
AR013693A1 (es) | Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria | |
ATE106401T1 (de) | Benzodiazepin-analoge. | |
SE8406585L (sv) | Bensoesyraderivat | |
CO4970713A1 (es) | Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen | |
ES2176204T3 (es) | Antidepresivos que contienen un derivado de xantina. | |
NO20013379L (no) | 4-okso-1,4-dihydro-3-kinolinkarboksamider som antivirusmidler | |
ES2120535T3 (es) | Agentes reticulantes con trifuncionalidad de carbamato. | |
MX9202142A (es) | Nuevos derivados de urea, proceso para su preparacion, y composicion farmaceutica que los comprende. | |
PE20010039A1 (es) | Derivados de esteres del acido carbamico como agonistas y/o antagonistas del receptor metabotropico del glutamato | |
CO5590895A2 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos | |
MX9302948A (es) | Imidazolinonas fungicidas y composicion fungicida que las contiene. | |
CO4930274A1 (es) | Tiazol bencenosulfonamidas como agonistas b3 para el trata- miento de la diabetes y la obesidad | |
DE69220133D1 (de) | N-Cyclohexyl Benzamide Derivate, ihre Herstellungen und therapeutischen Anwendungen | |
CO5080791A1 (es) | Derivados de la piperidina que tienen efectos sobre sistemas con serotonina | |
AR004965A1 (es) | Procedimiento de preparacion de derivados de fenilimidazolidina | |
DK0882726T3 (da) | Carbazolcarboxamider som 5-HT1F-agonister | |
CO4970752A1 (es) | Nuevos derivados de isatin y composiciones farmaceuticas conteniendo tales isatines | |
AR030239A1 (es) | Fta lidas substituidas, un procedimiento para su preparacion y composiciones farmaceuticas que contienen las mismas | |
ES2108595B1 (es) | Derivados de la 3(2h)-piridacinona y procedimiento para su preparacion. | |
FI852003L (fi) | --laktamantibiotika, foerfarande foer deras framstaellning och deras anvaendning som laekemedel eller tillvaextbefraemjare vid boskapsuppfoedning eller som antioxidanter. |